HA/CD44 promotes cancer cell survival and motility via AKT activation [37, 38], which is in line with our previous findings showing decreased expression of phosphorylated AKT with poor motility in tendinopathic tenocytes by blocking CD44 with an antagonizing antibody [3]. This evidence concerns the gene CD44 and cancer.